TITLE: Hyperthermic Intraperitoneal Chemotherapy for ... · Prolongs survival but is not curative...

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic review s. The intent is to

provide a list of sources of the best evidence on the topic that the Canadian Agency for Drugs and Technologies in Health (CADTH) could identify using all reasonable efforts within the time allow ed. Rapid responses should be considered along w ith other ty pes of information and health care considerations. The information included in this response is not intended to replace professional medical

advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for w hich little information can be found, but w hich may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not

make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report. Copyright: This report contains CADTH copyright material and may contain material in w hich a third party ow ns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a w eb site,

redistributed by email or stored on an electronic system w ithout the prior w ritten permission of CADTH or applicable copyright ow ner. Links: This report may contain links to other information available on the w ebsites of third parties on the Internet. CADTH does not

have control over the content of such sites. Use of third party sites is governed by the ow ners’ ow n terms and conditions.

TITLE: Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Clinical Effectiveness and Guidelines

DATE: 01 November 2016

RESEARCH QUESTIONS

1. What is the clinical effectiveness of hyperthermic intraperitoneal chemotherapy for the

treatment of peritoneal carcinomatosis?

2. What are the evidence-based guidelines regarding hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis?

KEY FINDINGS

Two systematic reviews, two randomized controlled trials, four non-randomized studies, and one evidence-based guideline were identified regarding hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis. METHODS

A limited literature search was conducted on key resources including PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, and guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2011 and October 17, 2016. Internet links were provided, where available. The summary of findings was prepared from the abstracts of the relevant information. Please note that data contained in abstracts may not always be an accurate reflection of the data contained within the full article.

Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis 2

SELECTION CRITERIA

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

Population Adult patients with peritoneal carcinomatosis/carcinosis

Intervention Hyperthermic intraperitoneal chemotherapy (HIPEC) Comparator Alternate cancer treatments (e.g., systemic chemotherapy),

placebo,

no treatment

Outcomes Clinical benefits and harms (e.g., survival, morbidity and mortality), guidelines

Study Designs Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies, evidence-based

guidelines

RESULTS

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, non-randomized studies, and evidence-based guidelines. Two systematic reviews, two randomized controlled trials, four non-randomized studies, and one evidence-based guideline were identified regarding hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis. No relevant health technology assessments were identified. Additional references of potential interest are provided in the appendix. OVERALL SUMMARY OF FINDINGS

Two relevant systematic reviews1,2 (SRs) were identified. One review1 examined the literature regarding hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of gastric peritoneal metastasis. The authors identified a small number of relevant trials and concluded that HIPEC may be effective when a complete, or almost complete, resection of the peritoneal metastases can be successfully done. The second SR2 focused on patients with colorectal cancer with liver and peritoneal metastases who underwent resection and HIPEC. The authors identified a trend towards an increase in median survival for patients who underwent resection of both types of metastases with HIPEC as compared to similar patients who underwent modern systemic chemotherapy. Two randomized controlled trials3,4 and four non-randomized studies5-8 were identified. The characteristics and results of these studies are summarized in Table 2. One guideline9 from the American Society of Colon and Rectal Surgeons was identified that recommends “the treatment of patients with peritoneal carcinomatosis should be


multidisciplinary and individualized and may include surgical cytoreduction. The role of intraperitoneal chemotherapy remains insufficiently defined.” (page 838)

Table 2: Summary of Clinical Study Results

First Author, Year

Patient Characteristics

Intervention and Comparator

Results and Authors’ Conclusions

Randomized Controlled Trials

Rudloff, 20143 Patients with measurable metastatic gastric adenocarcinoma involving the peritoneum N = 17

Gastrectomy, metastasectomy, HIPEC and systemic FOLFOXIRI versus FOLFOXIRI alone

Median OS was 11.3 months for the combined intervention and 4.3 months in the chemotherapy group

Two patients in the combined group survived beyond 12 months

Yang, 20114 Peritoneal carcinomatosis of gastric cancer N = 68

CRS + HIPEC versus CRS alone

Median survival o HIPEC group =

11.0 months o surgical group =

6.5 months

Median follow-up of 32 months o 85.3% of patients

in the HIPEC group had died

o 97.1% of patients in the surgical group had died

The authors suggested surgery + HIPEC may improve survival with acceptable morbidity

Non-Randomized Studies Boemer, 20165

Peritoneal carcinomatosis of gastric cancer N = 38

Gastrectomy + CRS + HIPEC versus Palliative management (with or without gastrectomy)

Median survival time o CRS + HIPEC =

17.2 months o Palliative = 11.0

months Two year survival

o CRS + HIPEC = 35.8%

o Palliative = 16.9%

Huang, 20146 Colorectal cancer peritoneal carcinomatosis

CRS + HIPEC versus

Complete cytoreduction o CRS + HIPEC =

42.4%


Table 2: Summary of Clinical Study Results

First Author, Year

Patient Characteristics

Intervention and Comparator

Results and Authors’ Conclusions

N = 62 CRS alone o CRS alone = 31.0%

Median OS o CRS + HIPEC =

13.7% o CRS alone = 8.5%

SAEs 30-days post-operative o CRS + HIPEC =

28.6% o CRS alone = 9.4%

The authors concluded that CRS + HIPEC could improve OS for these patients

Marcotte, 20147

Appendiceal peritoneal carcinomatosis N = 78

CRS + HIPEC (oxaliplatin) versus No CRS or HIPEC; Negative second-look with no HIPEC

5 year OS for the whole cohort = 66.2% o HIPEC = 77% o No HIPEC = 9% o Second-look =

100%

Cashin, 20128 Peritoneal carcinomatosis from colon cancer N = 32

HIPEC versus SPIC

Median OS o HIPEC = 36.5

months o SPIC = 23.9

months

Median disease-free survival o HIPEC = 22.8

months o SPIC = 13.0

months

Morbidity was not significantly different between groups

CRS = cytoreductive surgery; EPIC = early postoperative intraperitoneal chemotherapy; FOLFOXIRI = folinic acid, f luorouracil, oxaliplatin, irinotecan; HIPEC = hyperthermic intraperitoneal chemotherapy; OS = overall survival; SPIC = normothermic sequential postoperative intraperitoneal chemotherapy.


REFERENCES SUMMARIZED

Health Technology Assessments

No literature identified. Systematic Reviews and Meta-analyses

1. Di Vita M, Cappellani A, Piccolo G, Zanghi A, Cavallaro A, Bertola G, et al. The role of

HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows. Anticancer Drugs. 2015 Feb;26(2):123-38. PubMed: PM25406023

2. de Cuba EM, Kwakman R, Knol DL, Bonjer HJ, Meijer GA, Te Velde EA. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 2013 Jun;39(4):321-7. PubMed: PM23244778

Randomized Controlled Trials

3. Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, et al. Impact of

maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. PubMed: PM25042700

4. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol [Internet]. 2011 Jun [cited 2016 Oct 27];18(6):1575-81. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087875 PubMed: PM21431408

Non-Randomized Studies

5. Boerner T, Graichen A, Jeiter T, Zemann F, Renner P, Marz L, et al. CRS-HIPEC

Prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016 Nov;23(12):3972-7. PubMed: PM27313067

6. Huang CQ, Feng JP, Yang XJ, Li Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: a case-control study from a Chinese center. J Surg Oncol [Internet]. 2014 Jun [cited 2016 Oct 27];109(7):730-9. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283734 PubMed: PM24374987

http://www.ncbi.nlm.nih.gov/pubmed/25406023http://www.ncbi.nlm.nih.gov/pubmed/23244778http://www.ncbi.nlm.nih.gov/pubmed/25042700http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087875http://www.ncbi.nlm.nih.gov/pubmed/21431408http://www.ncbi.nlm.nih.gov/pubmed/27313067http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283734http://www.ncbi.nlm.nih.gov/pubmed/24374987


7. Marcotte E, Dube P, Drolet P, Mitchell A, Frenette S, Leblanc G, et al. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis. World J Surg Oncol [Internet]. 2014 Nov 7 [cited 2016 Oct 27];12:332. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233099 PubMed: PM25380618

8. Cashin PH, Graf W, Nygren P, Mahteme H. Intraoperative hyperthermic versus postoperative normothermic intraperitoneal chemotherapy for colonic peritoneal carcinomatosis: a case-control study. Ann Oncol. 2012 Mar;23(3):647-52. PubMed: PM21685413

Guidelines and Recommendations

9. Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD. Practice parameters for the

management of colon cancer. Dis Colon Rectum [Internet]. 2012 Aug [cited 2016 Oct 27];55(8):831-43. Available from: https://www.fascrs.org/sites/default/files/downloads/publication/practice_parameters_for_the_management_of_colon.21.pdf

See: Management of Peritoneal Carcinomatosis, page 838 PREPARED BY:

Canadian Agency for Drugs and Technologies in Health Tel: 1-866-898-8439 www.cadth.ca

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233099http://www.ncbi.nlm.nih.gov/pubmed/25380618http://www.ncbi.nlm.nih.gov/pubmed/21685413https://www.fascrs.org/sites/default/files/downloads/publication/practice_parameters_for_the_management_of_colon.21.pdfhttps://www.fascrs.org/sites/default/files/downloads/publication/practice_parameters_for_the_management_of_colon.21.pdfhttp://www.cadth.ca/


APPENDIX – FURTHER INFORMATION: Systematic Reviews – Only Executive Summary Available in English

10. Ubago‐Pérez R, Matas‐Hoces A, Beltrán‐Calvo C, Romero‐Tabares A. Hyperthermic intraperitoneal chemotherapy. Efficacy and safety in the treatment of ovarian cancer peritoneal carcino mitosis [Internet]. Seville: Andalusian Agency for Health Technology Assessment (AETSA); 2013 [cited 2016 Oct 27]. Available from: http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2012_6_HIPEC_eng.pdf

Clinical Practice Guidelines – Methodology Not Specified

11. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2014 Sep [cited 2016 Oct 27];25 Suppl 3:iii1-9. Available from: http://annonc.oxfordjournals.org/content/25/suppl_3/iii1.full.pdf See: page iii6

Consensus Statements

12. Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, et al. Consensus

guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014 May;21(5):1501-5. PubMed: PM23793364

Non-Randomized Studies

No Comparator Group

13. Hinkle NM, MacDonald J, Sharpe JP, Dickson P, Deneve J, Munene G. Cytoreduction

with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program. Am J Surg. 2016 Sep;212(3):413-8. PubMed: PM27086201

14. Honore C, Goere D, Macovei R, Colace L, Benhaim L, Elias D. Peritoneal carcinomatosis from unusual cancer origins: is there a role for hyperthermic intraperitoneal chemotherapy? J Visc Surg. 2016 Apr;153(2):101-7. PubMed: PM26698380

15. Liu L, Zhang N, Min J, Su H, Wang H, Chen D, et al. Retrospective analysis on the safety of 5,759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC). Oncotarget [Internet]. 2016 Apr 19 [cited 2016 Oct 27];7(16):21570-8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008306 PubMed: PM26919243

http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2012_6_HIPEC_eng.pdfhttp://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaaetsa/up/AETSA_2012_6_HIPEC_eng.pdfhttp://annonc.oxfordjournals.org/content/25/suppl_3/iii1.full.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/23793364http://www.ncbi.nlm.nih.gov/pubmed/27086201http://www.ncbi.nlm.nih.gov/pubmed/26698380http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008306http://www.ncbi.nlm.nih.gov/pubmed/26919243


16. Manzanedo I, Pereira F, Perez-Viejo E, Serrano A, Hernandez-Garcia M, Martinez-Torres B, et al. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Minerva Ginecol. 2016 Jul 14. [Epub ahead of print] PubMed: PM27415829

17. Munoz-Casares FC, Medina-Fernandez FJ, Arjona-Sanchez A, Casado-Adam A, Sanchez-Hidalgo JM, Rubio MJ, et al. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: long-term outcomes and perspectives from a high-volume center. Eur J Surg Oncol. 2016 Feb;42(2):224-33. PubMed: PM26673283

18. Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, et al. What

made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol. 2016 Jun;113(7):796-803. PubMed: PM27110915

19. Cardi M, Sammartino P, Mingarelli V, Sibio S, Accarpio F, Biacchi D, et al. Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis. World J Surg Oncol [Internet]. 2015 Oct 22 [cited 2016 Oct 27];13:305. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618525 PubMed: PM26493405

20. Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez CJ, et al. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol [Internet]. 2015 Jan [cited 2016 Oct 27];26(1):54-61. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302286 PubMed: PM25376916

21. Braam HJ, van Oudheusden TR, de Hingh I, Nienhuijs SW, Boerma D, Wiezer MJ, et al. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. J Surg Oncol. 2014 Jun;109(8):841-7. PubMed: PM24619813

22. Delotte J, Desantis M, Frigenza M, Quaranta D, Bongain A, Benchimol D, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis. Eur J Obstet Gynecol Reprod Biol. 2014 Jan;172:111-4. PubMed: PM24300558

23. Jafari MD, Halabi WJ, Stamos MJ, Nguyen VQ, Carmichael JC, Mills SD, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the American College of Surgeons National Surgical Quality Improvement Program. JAMA Surg. 2014 Feb;149(2):170-5. PubMed: PM24352601

http://www.ncbi.nlm.nih.gov/pubmed/27415829http://www.ncbi.nlm.nih.gov/pubmed/26673283http://www.ncbi.nlm.nih.gov/pubmed/27110915http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618525http://www.ncbi.nlm.nih.gov/pubmed/26493405http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302286http://www.ncbi.nlm.nih.gov/pubmed/25376916http://www.ncbi.nlm.nih.gov/pubmed/24619813http://www.ncbi.nlm.nih.gov/pubmed/24300558http://www.ncbi.nlm.nih.gov/pubmed/24352601


24. Jimenez WA, Sardi A, Nieroda C, Gushchin V. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent high-grade uterine sarcoma with peritoneal dissemination. Am J Obstet Gynecol. 2014 Mar;210(3):259-8. PubMed: PM24211479

25. Kuijpers AM, Mehta AM, Boot H, van Leerdam ME, Hauptmann M, Aalbers AG, et al. Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Oncol. 2014 Apr;25(4):864-9. PubMed: PM24667719

26. Robella M, Vaira M, Marsanic P, Mellano A, Borsano A, Cinquegrana A, et al. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Minerva Chir. 2014 Feb;69(1):27-35. PubMed: PM24675244

27. van Oudheusden TR, Braam HJ, Nienhuijs SW, Wiezer MJ, van Ramshorst B, Luyer MD, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis. Ann Surg Oncol. 2014 Aug;21(8):2621-6. PubMed: PM24671638

28. Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013 Dec;39(12):1435-43. PubMed: PM24209430

29. Bakrin N, Gilly FN, Baratti D, Bereder JM, Quenet F, Lorimier G, et al. Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. Eur J Surg Oncol. 2013 Jul;39(7):742-7. PubMed: PM23510853

30. Canda AE, Sokmen S, Terzi C, Arslan C, Oztop I, Karabulut B, et al. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013 Apr;20(4):1082-7. PubMed: PM23456387

Alternate Comparators 31. Alyami M, Lundberg P, Kepenekian V, Goere D, Bereder JM, Msika S, et al. Cytoreductive

surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly: a case-controlled, multicenter study. Ann Surg Oncol. 2016 Sep 6. [Epub ahead of print] PubMed: PM27600619

http://www.ncbi.nlm.nih.gov/pubmed/24211479http://www.ncbi.nlm.nih.gov/pubmed/24667719http://www.ncbi.nlm.nih.gov/pubmed/24675244http://www.ncbi.nlm.nih.gov/pubmed/24671638http://www.ncbi.nlm.nih.gov/pubmed/24209430http://www.ncbi.nlm.nih.gov/pubmed/23510853http://www.ncbi.nlm.nih.gov/pubmed/23456387http://www.ncbi.nlm.nih.gov/pubmed/27600619


32. Simkens GA, van Oudheusden TR, Braam HJ, Luyer MD, Wiezer MJ, van Ramshorst B, et al. Treatment-related mortality after cytoreductive surgery and HIPEC in patients with colorectal peritoneal carcinomatosis is underestimated by conventional parameters. Ann Surg Oncol. 2016 Jan;23(1):99-105. PubMed: PM26148758

33. Sun JH, Ji ZH, Yu Y, Wu HT, Huang CQ, Zhang Q, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat advanced/recurrent epithelial ovarian cancer: results from a retrospective study on prospectively established database. Transl Oncol [Internet]. 2016 Apr [cited 2016 Oct 27];9(2):130-8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833965 PubMed: PM27084429

34. Bommareddi SR, Simianu VV, Mann LV, Mann GN. High-quality results of cytoreductive surgery and heated intraperitoneal chemotherapy perfusion for carcinomatosis at a low volume institution. J Surg Oncol [Internet]. 2015 Aug [cited 2016 Oct 27];112(2):219-24. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655820 PubMed: PM26274508

35. Kuijpers AM, Aalbers AG, Nienhuijs SW, de Hingh I, Wiezer MJ, van Ramshorst B, et al. Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. World J Surg. 2015 Feb;39(2):453-60. PubMed: PM25245434

36. Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versus oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014 Dec;110(7):779-85. PubMed: PM25088304

37. Spiliotis JD, Halkia E, Boumis VA, Vassiliadou DT, Pagoulatou A, Efstathiou E. Cytoreductive surgery and HIPEC for peritoneal carcinomatosis in the elderly. Int J Surg Oncol [Internet]. 2014 [cited 2016 Oct 27];2014:987475. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009200 PubMed: PM24809147

Alternate Interventions 38. Huang Y, Alzahrani NA, Liauw W, Traiki TB, Morris DL. Early postoperative intraperitoneal

chemotherapy for low-grade appendiceal mucinous neoplasms with pseudomyxoma peritonei: is it beneficial? Ann Surg Oncol. 2016 Oct 7. [Epub ahead of print] PubMed: PM27718032

39. Maillet M, Glehen O, Lambert J, Goere D, Pocard M, Msika S, et al. Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol. 2016 Mar;23(3):863-9. PubMed: PM26480848

http://www.ncbi.nlm.nih.gov/pubmed/26148758http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833965http://www.ncbi.nlm.nih.gov/pubmed/27084429http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4655820http://www.ncbi.nlm.nih.gov/pubmed/26274508http://www.ncbi.nlm.nih.gov/pubmed/25245434http://www.ncbi.nlm.nih.gov/pubmed/25088304http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009200http://www.ncbi.nlm.nih.gov/pubmed/24809147http://www.ncbi.nlm.nih.gov/pubmed/27718032http://www.ncbi.nlm.nih.gov/pubmed/26480848


40. Lam JY, McConnell YJ, Rivard JD, Temple WJ, Mack LA. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Am J Surg. 2015 Sep;210(3):424-30. PubMed: PM26051744

41. Sparks DS, Morris B, Xu W, Fulton J, Atkinson V, Meade B, et al. Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix. Int Surg [Internet]. 2015 Jan [cited 2016 Oct 27];100(1):21-8. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301290 PubMed: PM25594636

42. Glockzin G, von Breitenbuch P, Schlitt HJ, Piso P. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. J Surg Oncol. 2013 May;107(6):574-8. PubMed: PM22833286

Quality of Life 43. Chia CS, Tan GH, Lim C, Soo KC, Teo MC. Prospective quality of life study for colorectal

cancer patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016 Sep;23(9):2905-13. PubMed: PM27016293

44. Ford J, Hanna M, Boston A, Berri R. Life after hyperthermic intraperitoneal chemotherapy; measuring quality of life and performance status after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Am J Surg. 2016 Mar;211(3):546-50. PubMed: PM26778767

Review Articles

45. Feingold PL, Kwong ML, Sabesan A, Sorber R, Rudloff U. Cytoreductive surgery and

hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time? J Gastrointest Oncol [Internet]. 2016 Feb [cited 2016 Oct 27];7(1):87-98. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754313 PubMed: PM26941987

46. Li Y, Zhou YF, Liang H, Wang HQ, Hao JH, Zhu ZG, et al. Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol [Internet]. 2016 Aug 14 [cited 2016 Oct 27];22(30):6906-16. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974588 PubMed: PM27570426

47. Polom K, Roviello G, Generali D, Marano L, Petrioli R, Marsili S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. Int J Hyperthermia. 2016 May;32(3):298-310. PubMed: PM26984715

http://www.ncbi.nlm.nih.gov/pubmed/26051744http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301290http://www.ncbi.nlm.nih.gov/pubmed/25594636http://www.ncbi.nlm.nih.gov/pubmed/22833286http://www.ncbi.nlm.nih.gov/pubmed/27016293http://www.ncbi.nlm.nih.gov/pubmed/26778767http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754313http://www.ncbi.nlm.nih.gov/pubmed/26941987http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974588http://www.ncbi.nlm.nih.gov/pubmed/27570426http://www.ncbi.nlm.nih.gov/pubmed/26984715


48. Rajeev R, Turaga KK. Hyperthermic intraperitoneal chemotherapy and cytoreductive surgery in the management of peritoneal carcinomatosis. Cancer Control. 2016 Jan;23(1):36-46. PubMed: PM27009455

49. Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol [Internet]. 2016 Jan 21 [cited 2016 Oct 27];22(3):1114-30. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716024 PubMed: PM26811651

50. Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O. Hyperthermic intraperitoneal

chemotherapy (HIPEC) in ovarian cancer. J Visc Surg. 2014 Oct;151(5):347-53. PubMed: PM25168575

51. Montori G, Coccolini F, Ceresoli M, Catena F, Colaianni N, Poletti E, et al. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. Int J Surg Oncol [Internet]. 2014 [cited 2016 Oct 27];2014:912418. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947693 PubMed: PM24693422

52. Di Miceli D, Alfieri S, Caprino P, Menghi R, Quero G, Cina C, et al. Complications related to hyperthermia during hypertermic intraoperative intraperitoneal chemiotherapy (HIPEC) treatment. Do they exist? Eur Rev Med Pharmacol Sci. 2012 Jun;16(6):737-42. PubMed: PM22913203

http://www.ncbi.nlm.nih.gov/pubmed/27009455http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716024http://www.ncbi.nlm.nih.gov/pubmed/26811651http://www.ncbi.nlm.nih.gov/pubmed/25168575http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947693http://www.ncbi.nlm.nih.gov/pubmed/24693422http://www.ncbi.nlm.nih.gov/pubmed/22913203

Research QuestionsKey FindingsMethodsResultsOverall Summary of FindingsReferences SummarizedAppendix – Further information:

Date post:	11-Jun-2020
Category:	Documents
Upload:	others
View:	1 times
Download:	0 times

TITLE: Hyperthermic Intraperitoneal Chemotherapy for ... · Prolongs survival but is not curative...

Documents